Anti-cancer drugs, olaparib and adavosertib, work best when given sequentially in patients with advanced tumours driven by DNA damage response mutations: results from Phase Ib STAR clinical trial
Barcelona, Spain: Patients with cancers that are driven by certain mutations occurring in response to DNA damage can be safely ...
